Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine

Chen, Grace; Nomikos, George G.; Affinito, John; Jacobson, W.; Zhao, Zhen; Wang, Shining; Xie, Jiaheng

doi:10.1002/cpdd.577

Cited by 7 publications

(3 citation statements)

References 19 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a phase 4 double-blind randomized, controlled trial, the novel antidepressant vortioxetine was shown to be associated with less TESD than paroxetine [177]. It appears that its pharmacokinetics are not altered by renal or hepatic impairment [178], and dose-adjustment is not necessary in the setting of CKD and ESRD [179].…”

Section: Iatrogenic Sdmentioning

confidence: 99%

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Chou

Kiebalo

Jagiello

et al. 2021

Life

View full text Add to dashboard Cite

Patient survival continues to increase with the growing quality of dialysis and management of chronic kidney disease (CKD). As such, chronic therapy must include considerations of quality of life (QOL), and this includes the disproportionate prevalence of sexual dysfunction (SD) in this patient population. This review aims to describe the pathophysiological and the psychosocial causes of SD with regard to renal replacement therapy, particularly hemo- and peritoneal dialysis. The differences in its manifestation in men and women are compared, including hormonal imbalances—and therefore fertility, libido, and sexual satisfaction—the experience of depression and anxiety, and QOL. The impact of comorbidities and the iatrogenic causes of SD are described. This review also presents validated scales for screening and diagnosis of SD in CKD patients and outlines novel therapies and strategies for the effective management of SD. Increased prevalence of CKD invariably increases the number of patients with SD, and it is crucial for health care professional teams to become familiar with the clinical tools used to manage this sensitive and under-quantified field. As a known predictor of QOL, sexual function should become a point of focus in the pursuit of patient-centered care, particularly as we seek to achieve as “normal” a life as possible for individuals who receive dialysis.

show abstract

Section: Iatrogenic Sdmentioning

confidence: 99%

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Chou

Kiebalo

Jagiello

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…23 Vortioxetine is primarily metabolized by the CYP2D6 enzyme, and less so by CYP2C19, but, given that the ratios of maximum plasma concentration for the inhibitor (vortioxetine or its metabolites) and the dissociation constant of the inhibitor (Ki) were far below 0.1, the inhibition is considered clinically irrelevant. [23][24][25] Nonetheless, it cannot be ruled out that concomitant use of vortioxetine and paroxetine may have resulted in increased plasma concentrations of the former as a result of significant CYP2D6 inhibition by the latter.…”

Section: Discussionmentioning

confidence: 99%

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study

Berardis¹,

Fornaro

Anastasia

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD. Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression-Improvement module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission. Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale for Suicide Ideation (SSI). Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales). Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant depression. However, the limitations of this study (such as small sample size, absence of randomization and control group, retrospective design, etc.) must be considered.

show abstract

“…Moreover, among studies of vortioxetine in generalized anxiety disorder (GAD) (n = 5), three 8-week trials exhibited negative results [78][79][80], while 8-week and 20-week trials showed a significant benefit over placebo [81,82]. Key information derived from experimental pharmacokinetics studies (n = 7) is summarized in Table 5 [83][84][85][86][87][88][89]. Vortioxetine metabolism does not differ between sexes.…”

Section: Experimental Studiesmentioning

confidence: 99%

The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature

Weiss,

Pacciardi,

D’Alessandro

et al. 2024

JCM

View full text Add to dashboard Cite

Depressive symptoms are a customary finding in hospitalized patients, particularly those who are undergoing long hospitalizations, underwent major surgical procedures or suffer from high levels of multimorbidity and frailty. The patients included in this case series shared high degrees of frailty-complexity and were evaluated within the ordinary consultation and liaison psychiatry service of the University Hospital in Pisa, Italy, from September 2021 to June 2023. Patients were administered at least one follow-up evaluation after a week and before discharge. To relate this case series to the extant literature, a comprehensive systematic review of vortioxetine safety and efficacy was performed. None of the six patients included developed serious safety issues, but one patient complained of mild-to-moderate nausea for some days after the vortioxetine introduction. Five out of six patients exhibited at least a slight clinical benefit as measured by the clinical global impression scale. Of the 858 entries screened via Scopus and Medline/PubMed, a total of 134 papers were included in our review. The present case series provides preliminary evidence for vortioxetine’s safety in this healthcare domain. The literature reviewed in this paper seems to endorse a promising safety profile and a very peculiar efficacy niche for vortioxetine in consultation and liaison psychiatry.

show abstract

Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine

Cited by 7 publications

References 19 publications

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study

The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature

Contact Info

Product

Resources

About